Delcath Systems's ROE % for the quarter that ended in Mar. 2026 was -3.82%. Delcath Systems's PB Ratio for the quarter that ended in Mar. 2026 was 2.84.
Delcath Systems's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -1.35%.
Delcath Systems ROE % Adjusted to Book Value Related Terms
Delcath Systems ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Delcath Systems's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Delcath Systems ROE % Adjusted to Book Value Chart
DCTH vs OFIX, VMD, CLPT: ROE % Adjusted to Book Value Comparison
For the Medical Devices subindustry, Delcath Systems's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delcath Systems ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Delcath Systems's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -1.35% mean?
Delcath Systems (DCTH) has a ROE % Adjusted to Book Value of -1.35% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Delcath Systems and its competitors.
Is Delcath Systems' ROE % Adjusted to Book Value too high?
Delcath Systems' current ROE % Adjusted to Book Value is -1.35%. Overall, Delcath Systems has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Delcath Systems' ROE % Adjusted to Book Value compare to OFIX and VMD?
Delcath Systems' ROE % Adjusted to Book Value of -1.35% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Delcath Systems and its competitors. Delcath Systems's current ROE % Adjusted to Book Value is -1.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delcath Systems stock overvalued right now?
Based on GuruFocus' analysis, Delcath Systems (DCTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $36.72, compared to a current price of $12.94 — trading 64.8% below its estimated fair value. The current ROE % Adjusted to Book Value is -1.35%. Delcath Systems' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Delcath Systems (DCTH), the current ROE % Adjusted to Book Value is -1.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Delcath Systems (DCTH) Overvalued in 2026?
Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued.
The current stock price of $12.94 is trading 64.8% below its estimated GF Value™ of $36.72.
GuruFocus considers Delcath Systems to be Significantly Undervalued.
Key valuation signals for DCTH:
ROE % Adjusted to Book Value: -1.35%
GF Value™: $36.72 vs. price of $12.94 (64.8% below fair value)
No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
70GF Score
Get the complete analysis for DCTH
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCTH has been successfully added to your 
